Innoviva Income Taxes 2010-2023 | INVA

Innoviva income taxes from 2010 to 2023. Income taxes can be defined as the total amount of income tax expense for the given period.
Innoviva Annual Income Taxes
(Millions of US $)
2023 $14
2022 $67
2021 $76
2020 $60
2019 $42
2018 $-196
2017 $0
2016 $0
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Innoviva Quarterly Income Taxes
(Millions of US $)
2023-12-31 $-0
2023-09-30 $4
2023-06-30 $5
2023-03-31 $6
2022-12-31 $4
2022-09-30 $57
2022-06-30 $-1
2022-03-31 $7
2021-12-31 $11
2021-09-30 $21
2021-06-30 $25
2021-03-31 $20
2020-12-31 $16
2020-09-30 $9
2020-06-30 $20
2020-03-31 $16
2019-12-31 $12
2019-09-30 $11
2019-06-30 $10
2019-03-31 $9
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30 $-0
2014-06-30 $0
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.948B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $688.746B 114.69
Novo Nordisk (NVO) Denmark $564.487B 46.50
Johnson & Johnson (JNJ) United States $353.804B 14.04
Merck (MRK) United States $331.117B 60.24
AbbVie (ABBV) United States $296.212B 15.06
AstraZeneca (AZN) United Kingdom $232.626B 20.22
Novartis AG (NVS) Switzerland $202.479B 14.36
Pfizer (PFE) United States $143.036B 13.80
Sanofi (SNY) $124.861B 11.78